Tradestie Institutional Equity Comparison Engine · Market Close Nov 09, 2026

ACHV vs TBPH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TBPH Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)

TBPH Overall Winner 6-Pillar Tally: ACHV 1 – 5 TBPH Matrix Metrics: ACHV 3 – 7 TBPH

As of Nov 09, 2026, Theravance Biopharma, Inc. (TBPH) is the stronger overall head-to-head candidate over Achieve Life Sciences, Inc. (ACHV) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ACHV carries a Unified Composite Score of 56.6/100 (HOLD) at $6.78 (35.3x Forward P/E, 0.0% operating margin), whereas TBPH carries 54.9/100 (HOLD) at $17.03 (13.4x Forward P/E, 8.9% operating margin).

  • Composite vs. Pillar Nuance: While ACHV currently prints a higher short-term Unified Composite Score (56.6/100 HOLD vs. TBPH 54.9/100 HOLD), TBPH captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (8.9% vs. 0.0% operating margin) and revenue trajectory (-20.9% vs. +0.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ACHV vs TBPH
ACHV NASDAQ
Achieve Life Sciences, Inc.
In Vitro & In Vivo Diagnostic Substances
$6.78
+0.89% 1D
Market Cap $692.8M
TTM Revenue N/A
Forward P/E 35.3x
Beta / 30D Vol 1.73β · 62% Vol
Unified Composite Score
56.6 / 100 HOLD
Tech 66.0 Fund 58.0 Flow 57.0 Mom 58.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 48.1 · SMA20: $6.72 · SMA50: $7.28
TBPH NASDAQ Head-to-Head Winner
Theravance Biopharma, Inc.
Pharmaceutical Preparations
$17.03
+0.0% 1D
Market Cap $884.2M
TTM Revenue $104M
Forward P/E 13.4x
Beta / 30D Vol 0.48β · 2% Vol
Unified Composite Score
54.9 / 100 HOLD
Tech 65.0 Fund 52.0 Flow 50.0 Mom 35.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 53.6 · SMA20: $17.04 · SMA50: $16.96

6-Pillar Scorecard Institutional Category Breakdown (ACHV 1 – 5 TBPH)

Columns: Metric · ACHV · TBPH
1. Valuation Multiples TBPH
Forward P/E 35.3x 13.4x
Trailing P/E 35.3x 16.4x
PEG Ratio 17.68x N/M
EV / Revenue N/M 8.5x
2. Growth & Scale TBPH
Revenue Growth (YoY) +0.0% -20.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $104M
Market Cap $692.8M $884.2M
3. Profitability & Quality TBPH
Gross Margin N/A 75.1%
Operating Margin 0.0% 8.9%
Net Profit Margin 0.0% 51.6%
Return on Equity (ROE) -845.0% 20.9%
4. Balance Sheet & Cash Flow TBPH
Cash Generation (TTM) -$44M $11M EBITDA
Cash Flow Margin N/A 10.6% EBITDA Mgn
Net Cash / Leverage $46M Net Cash $5.58 Book/Sh · 20.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ACHV
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 88.3% (23rd %ile) 55.0% (16th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat TBPH
OpEx & R&D Intensity N/A 66.2% of Rev ($69M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ACHV (3) vs TBPH (7)
Institutional Metric ACHV TBPH Criterion Row Edge
Market Capitalization
Scale
$692.8M $884.2M Larger Scale TBPH
Trailing P/E Ratio
Valuation
35.3x 16.4x Lower Multiple TBPH
Forward P/E Ratio
Valuation
35.3x 13.4x Lower Multiple TBPH
Revenue Growth (YoY)
Growth
+0.0% -20.9% Higher Growth ACHV
Operating Margin (TTM)
Profitability
0.0% 8.9% Higher Margin TBPH
Net Profit Margin
Profitability
0.0% 51.6% Higher Margin TBPH
Return on Equity (ROE)
Capital Efficiency
-845.0% 20.9% Higher ROE TBPH
52-Week Range Position
Momentum
69% ($3–$9) 50% ($13–$21) Stronger Trend ACHV
Beta / 30D Volatility
Risk Regime
1.73β · 62% Vol 0.48β · 2% Vol Lower Realized Risk TBPH
Unified Institutional Score
Composite Signal
56.6 / 100 (HOLD) 54.9 / 100 (HOLD) Higher Composite ACHV
Trailing 12M Revenue (USD)
Operating Scale
N/A $104M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 75.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
17.68x PEG · N/M EV/Rev N/M PEG · 8.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$44M ($46M Net Cash) $11M EBITDA ($5.58 Book/Sh · 20.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TBPH +1.51 pp
ACHV: -1.39% · TBPH: +0.12%
3M Horizon ACHV +49.13 pp
ACHV: +47.74% · TBPH: -1.39%
6M Horizon ACHV +155.7 pp
ACHV: +170.0% · TBPH: +14.3%
1Y Horizon ACHV +50.66 pp
ACHV: +65.19% · TBPH: +14.53%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACHV vs TBPH. Trailing 12-month operating profitability (ACHV 0.0% vs TBPH 8.9%) and valuation multiples (ACHV 35.3x vs TBPH 13.4x Forward P/E) are benchmarked directly in Pillar 4 below.

ACHV ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-845.0% · 35.3x
TBPH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$104M
Gross Margin75.1%
Op. Margin8.9%
ROE / Fwd P/E20.9% · 13.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ACHV BREAKOUT
125d in phase · OBV NEUTRAL
Current IV 88.3%
IV Percentile 23rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ACHV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TBPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 55.0%
IV Percentile 16th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TBPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ACHV Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $692.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TBPH Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $884.2M market capitalization and 8.9% operating margin.
OpEx & R&D Reinvestment 66.2% of Rev ($69M)
90D Engineering Disclosures 0 Published

Investor FAQ ACHV vs TBPH Key Questions & Quantitative Answers

As of Nov 09, 2026, Theravance Biopharma, Inc. (TBPH) is the stronger overall head-to-head candidate over Achieve Life Sciences, Inc. (ACHV) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ACHV carries a Unified Composite Score of 56.6/100 (HOLD) at $6.78 (35.3x Forward P/E, 0.0% operating margin), whereas TBPH carries 54.9/100 (HOLD) at $17.03 (13.4x Forward P/E, 8.9% operating margin). Composite vs. Pillar Nuance: While ACHV currently prints a higher short-term Unified Composite Score (56.6/100 HOLD vs. TBPH 54.9/100 HOLD), TBPH captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (8.9% vs. 0.0% operating margin) and revenue trajectory (-20.9% vs. +0.0% YoY).

TBPH leads the Growth & Scale pillar: ACHV posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with TBPH at -20.9% YoY revenue growth and +0.0% YoY earnings growth on $104M TTM revenue (75.1% gross margin, 8.9% operating margin). On trailing 12-month operating scale, ACHV generates N/A in USD-normalized revenue versus $104M for TBPH. In operating R&D and SG&A reinvestment, ACHV deploys N/A (0 90-day corporate R&D disclosures) versus 66.2% of Rev ($69M) (0 disclosures) for TBPH.

TBPH screens cheaper on headline valuation multiples. ACHV trades at 35.3x Forward P/E, 35.3x Trailing P/E, 17.68x PEG, and N/M EV/Revenue (unreported FCF margin), whereas TBPH trades at 13.4x Forward P/E, 16.4x Trailing P/E, N/M PEG, and 8.5x EV/Revenue (10.6% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ACHV (-845.0% ROE) versus TBPH (20.9% ROE) capital efficiency.

In options market volatility and institutional positioning, ACHV carries 88.3% implied volatility (23rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (1.73β · 62% Vol realized risk). By comparison, TBPH carries 55.0% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.48β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 09, 2026. For educational research only; not investment advice.